Recruiting
Phase 1

OPT101

Sponsor:

Op-T LLC

Code:

NCT06669403

Conditions

Sepsis

Community Acquired Pneumonia (CAP)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

OPT101

Placebo

Study Details

Brief summary:

OPT101-100-40 is a multicenter, randomized, placebo-controlled, multiple-ascending-dose, sequential-group, investigator- and participant-blinded, sponsor-unblinded, study of OPT101 vs placebo when administered for up to 4 days to patients admitted to the hospital for treatment of Community Acquired Pneumonia (CAP) with sepsis.

This study will be performed in patients with Community Acquired Pneumonia (CAP) with Sepsis, who are 18 years or older to evaluate the safety and tolerability of OPT101 in a population with elevated levels of pathologic CD40.

Conditions

Sepsis

Community Acquired Pneumonia (CAP)

Study ID

NCT06669403

Start date

Mar 9, 2026

Status verified date

Nov, 2026

Completion date

Mar, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Are able and willing to give signed informed consent (legally authorized representative can provide informed consent if needed).
2. ≥18 years old;
3. Patients hospitalized for clinically suspected community acquired pneumonia (CAP), defined as the occurrence of (within 48h from hospital admission) at least 1 of the following signs:

  • respiratory rate > 30 breaths/min;
  • fever (> 38.0°C or > 100.4° F);
  • leukopenia (≤ 4,000 WBC/mm3 or leukocytosis (≥ 12,000 WBC/mm3);
  • adults ≥ 70 years of age; altered mental status with no other recognized cause;

AND at least 1 of the following:
  • New onset of purulent sputum or change in character of sputum or increased respiratory secretions;
  • New onset or worsening cough, or dyspnea, or tachypnea;
  • Rales or bronchial breath sounds; AND Radiologic imaging (chest x-ray or CT scan) evidence of pulmonary involvement with new and persistent or progressive and persistent infiltrate, consolidation or cavitation AND SpO2 <92% at room air, or PaO2/FiO2 (or SpO2/FiO2) <300; recorded on one episode
4. Need for non-invasive supplemental oxygen (nasal cannula, simple mask, venturi or reservoir cannula/mask or heated high flow nasal cannula oxygen.
5. Females of child-bearing potential who are sexually active must not wish to get pregnant within 30 days after the end of the study and must be using at least one of the following reliable methods of contraception:

  • Hormonal contraception, systemic, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit until 30 days after the last OPT101 dose
  • A non-hormonal intrauterine device \[IUD\] or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit until 30 days after the last OPT101 dose
  • A male sexual partner who agrees to use a male condom with spermicide
  • A sterile sexual partner

Exclusion Criteria:

1. Need for endotracheal intubation and mechanical ventilation or extracorporeal membrane oxygenation (ECMO) at time of study screening
2. QTc ≥ 450 msec on screening ECG
3. Hepatic dysfunction: ALT or AST > 5 ULN; history of chronic hepatic disease (defined with Child-Pugh score ≥ 12)
4. Recent or active hepatitis A infection; test positive or have been treated for hepatitis B, hepatitis C, or HIV infection; evidence of active or untreated latent TB; a recent history of recurrent herpes zoster and/or opportunistic infection; and/or taking immunosuppressant medication.
5. Renal dysfunction: estimated glomerular filtration rate (eGFR) <50 mL/min/1.73 m2, or need for hemodialysis or hemofiltration
6. Current use of >2 immunosuppressive medications or immunosuppression status (AIDS, aplastic anemia, asplenia, systemic chemotherapy within the past 3 months, neutropenia (ANC < local LLN), solid organ or bone marrow transplant recipients)
7. Treatment with prohibited medication within 5 half-lives, and inability to stop during treatment period
8. Anticipated discharge from the hospital or transfer to another hospital within 48 hours of screening
9. Allergy to OPT101or any component of OPT101 formulation
10. Participation in other interventional clinical trials
11. Pregnancy:

  • positive or missing pregnancy test before first drug intake or day 1
  • pregnant or lactating women;
  • Women of childbearing potential and fertile men who do not agree to use at least one primary form of contraception for the duration of the study
12. Current hospital stay >72h
13. Complicated CAP-associated conditions, such as fungal pulmonary infection, tuberculosis infection, abscess, empyema, significant bilateral pleural effusion, massive pulmonary embolism
14. Weight is over 250lbs
15. Any other condition which the Principal Investigator feels may jeopardize the safety of the patient or the objectives of the study. The Principal Investigator should make this determination in consideration of the patient's medical history and current clinical condition.

\-

Study Design

Enrollment

26 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

placebo comparator: 0.9% Sodium Chloride Injection USP

Placebo will be 50mL normal saline (Sodium Chloride), USP sterile solution provided in a 50mL pre-packaged Intravenous (IV) bag.

experimental: OPT101

OPT101 (15-mer peptide) will be provided across 2 cohorts at 1.1 (cohort 1) and 2.8 mg/kg (cohort 2) doses . On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Interventions

OPT101

OPT101, is a 15-mer peptide derived from the sequence of mouse CD40L and was designed to target CD40-mediated inflammation. On the day of administration, the product will be diluted in saline to result in 50 mL for intravenous (IV) infusion over 120 minutes.

Placebo

0.9% Sodium Chloride Injection USP, Placebo. On the day of administration, a 50mL IV bag containing saline (0.9% Sodium Chloride Injection USP) which will serve as the placebo will be administered via intravenous (IV) infusion over 120 minutes.

Primary outcome measure

  • Incidence of treatment-emergent adverse events (TEAEs) [ Time Frame: 30 days ]
  • Incidence of serious adverse events (SAEs) [ Time Frame: 30 days ]
  • Incidence of TEAEs leading to study drug discontinuation [ Time Frame: 30 days ]
  • Incidence and characteristics of presumed infusion reactions [ Time Frame: 30 days ]

Central Contacts and Locations

Central contacts

Locations

Westchester Medical Center

Recruiting

Valhalla, New York, United States, 10595

More Information

Sponsor

Op-T LLC

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • Sepsis
  • Community Acquired Pneumonia (CAP)
  • Immunomodulator
  • OPT101
  • Op-T LLC

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Op-T LLC on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.